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Abstract
Background: QuantiFERON-TB Gold In-Tube (QFT) is an IFNc-release assay used in the diagnosis of Mycobacterium
tuberculosis (MTB) infection. The risk of TB progression increases with the magnitude of the MTB-specific IFNc-response. QFT
reversion, also associated with low Tuberculin Skin Test responses, may therefore represent a transient immune response
with control of M. tuberculosis infection. However, studies at the single cell level have suggested that the quality
(polyfunctionality) of the T-cell response is more important than the quantity of cytokines produced.
Objective: To explore the quality and/or magnitude of mycobacteria-specific T-cell responses associated with QFT reversion
and persistent QFT-positivity.
Methods: Multi-color flowcytometry on prospectively collected peripheral blood mononuclear cells was applied to assess
mycobacteria-specific T-cell responses in 42 QFT positive Indian adolescents of whom 21 became QFT negative (reverters)
within one year. Ten QFT consistent negatives were also included as controls.
Results: There was no difference in the qualitative PPD-specific CD4+ T-cell response between QFT consistent positives and
reverters. However, compared with QFT consistent positives, reverters displayed lower absolute frequencies of
polyfunctional (IFNc+IL2+TNFa+) CD4+ T-cells at baseline, which were further reduced to the point where they were not
different to QFT negative controls one year later. Moreover, absolute frequencies of these cells correlated well with the
magnitude of the QFT-response.
Conclusion: Whereas specific polyfunctional CD4+ T-cells have been suggested to protect against TB progression, our data
do not support that higher relative or absolute frequencies of PPD-specific polyfunctional CD4+ T-cells in peripheral blood
can explain the reduced risk of TB progression observed in QFT reverters. On the contrary, absolute frequencies of these
cells correlated with the QFT-response, suggesting that this readout reflects antigenic load.
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Introduction
One third of the world’s population is estimated to be infected
with Mycobacterium tuberculosis (MTB) [1]. These individuals
constitute a huge reservoir for continued transmission as well as
morbidity and mortality due to tuberculosis (TB). Latently infected
individuals (LTBI) who do not progress to tuberculosis have been
assumed to possess natural protective immunity. Therefore, the
immune responses in subjects with latent MTB infection have
been extensively studied in order to identify surrogate markers of
protection against TB for use in vaccine efficacy trials [2,3] and
risk assessment for TB progression in LTBI subjects, enabling
better targeted preventive treatment [4].
QuantiFERON-TB Gold In-Tube (QFT) is an ex vivo interferon
gamma-release assay (IGRA) increasingly used for the diagnosis of
latent MTB infection in adults, as it provides specificity superior to
the Tuberculin Skin Test (TST) in populations where the BCG-
vaccine is administered after infancy [4]. There is extensive
evidence for a positive correlation between the size of the TST
induration and TB risk [5,6], but studies are emerging claiming
equal or superior predictive power for TB outcome by IGRAs
(reviewed in [4]). The risk of TB progression seems to increase
with the magnitude of MTB-specific IFNc-responses[7–11].
Accordingly, specific IFNc-responses seem to be higher in subjects
with active TB, where MTB is thought to be actively replicating
[12,13].
In longitudinal studies of TB exposed individuals, 20–60% of
those that are IGRA-positive at baseline revert to IGRA-negative
(reviewed in [4] ). IGRA reversion is more likely in subjects with a
negative TST[14–18] and/or IFNc-responses close to the test cut-
off [14,17]. The immunological and clinical significance of IGRA
reversion is debated: Is it simply a matter of fluctuation around the
test cut-off? Does MTB-reactive IFNc-production reduce over
time due to pathogen clearance or dormancy/latency? Does latent
MTB occasionally secrete antigens, keeping the immune response
boosted? And importantly, are reverters protected against
reactivation or re-infection? (Reviewed in [19]).
Based on analogy to findings in the field of virology [20] and
Leishmania major infection in mice [21], it has been suggested that
polyfunctional CD4+ T-cells (producing IFNc, TNFa and IL2)
protect MTB infected subjects from TB progression (reviewed in
[22]). The occurrence of mycobacteria-specific polyfunctional
CD4+ T-cells has therefore been used to evaluate new vaccine
candidates in mice [23,24] and humans [25]. In a recent cross-
sectional study it was shown that LTBI subjects had an increased
proportion of mycobacteria-specific polyfunctional CD4+ T-cells
in peripheral blood compared to TB patients, whereas the latter
displayed a high proportion of TNFa-single-producing T-cells
[26]. Although the risk of TB progression increases with the
magnitude of the MTB-specific IFNc-response [7–10], the
findings by Harari et al (26) may suggest that the quality of the
T-cell response is more important than the quantity of cytokines
produced.
Supported by epidemiological studies which report reduced
QFT and TST responses in subjects who later revert to QFT
negative [14–18], we assumed that QFT reversion represents a
successful immune response and reduced risk of TB progression
after MTB infection. Accordingly, we hypothesized that QFT
reverters differ from QFT consistent positives with regard to the
quality and magnitude of MTB-specific T-cell responses in
peripheral blood. By characterizing the likely favourable immune
response of QFT reverters, we aimed to make a contribution in the
search for biomarkers predicting TB outcome in LTBI subjects.
Therefore, in the context of a prospective cohort study in Indian
adolescents we compared mycobacteria-specific T-cell responses in
blood samples obtained from QFT consistent positives and QFT
reverters.
Methods
Study setting
Data and samples for the present study were collected in the
context of the Adolescent Cohort Study (ACS), a prospective,
observational study conducted by the TB Trials Study Group in
India to establish the incidence of TB in adolescents and prepare
the field site for future vaccine trials. In India, BCG vaccination is
advocated at birth. The ACS enrolled 6644 adolescents aged 12–
18 years from randomly selected school clusters within a typical
Figure 1. QuantiFERON Gold In-Tube (QFT) and Tuberculin Skin Test (TST) responses. (A) The magnitude of the QFT response and (B) the
TST response in QFT consistent positives (n = 21), QFT reverters (n = 21) and QFT negative controls (n = 10) at baseline (BL) and after 1 year. Unpaired
and paired analyses was performed with Mann-Whitney U test and Wilcoxon Signed rank test where appropriate. Horizontal lines represent median
values.
doi:10.1371/journal.pone.0101224.g001
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rural/semi-urban South-Indian population (Palamaner Taluk,
Andhra Pradesh). Written informed consent from parents and
written assent from participants was obtained at the time of
recruitment. Active TB was excluded at inclusion. The partici-
pants were randomized (by school clusters) to a 2-year active or
passive surveillance. Participants with active surveillance
(n = 3102) were eligible for the present study. These subjects had
a TST administered and read after 48–72 hours by a trained nurse
or physician (2 TU/0.1 mL tuberculin; Span Diagnostics Ltd,
India) at study inclusion, day 360 and 720. QuantiFERON- TB
Gold In-Tube (QFT) assay (Cellestis) was added to the original
study protocol at study day 360 and 720. The QFT assay was
Figure 2. Qualitative and quantitative analysis of PPD-specific CD4+CD45RO+ T-cell responses in QFT consistent positives and QFT
reverters. (A) The relative frequencies of the PPD-specific CD4+CD45RO+ T-cell subsets in QFT consistent positives (red symbols) and QFT reverters
(blue symbols) at baseline (filled) (n = 16, n = 7) and after 1 year (open) (n = 6, n = 6). The subsets are defined on the basis of IFNc, TNFa and/or IL-2
production. Since relative frequencies are normalized data, un-paired T-test with Welch’s correction was applied for statistical analyses and horizontal
lines represent mean values. (B) The absolute frequencies of PPD-specific CD4+CD45RO+ T- in QFT consistent positives (red symbols) and QFT
reverters (blue symbols) at baseline (filled) (n = 16, n = 7) and after 1 year (open) (n = 6, n = 6). As the data are not normally distributed, statistical
analyses were performed by the Mann-Whitney U test and horizontal lines represent median values. (C) Flowcytometric plots of the functional profile
of PPD-specific CD4+CD45RO+ T-cells compared with negative (PBS) and positive (SEB) control in one representative QFT consistent positive subject
are shown.
doi:10.1371/journal.pone.0101224.g002
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performed on 3 ml of peripheral blood according to the
manufacturer’s instructions. The subjects were clinically assessed
for TB every 3rd month and peripheral blood was obtained every
6th month for isolation of peripheral blood mononuclear cells
(PBMCs).
For the present study, healthy adolescents were randomly
selected based on the QFT results from day 360 (hereafter referred
to as the QFT baseline) and 1 year later (day 720). A positive QFT
was defined as an IFNc-response $0.35 IU/ml. 21 QFT
consistent positives, 21 QFT reverters (QFT positive at baseline
and QFT negative (,0.35 IU/ml) 1 year later) and 10 consistent
negative controls were included. The mean age of the study
participants was 13.3 years (SD 1.01) and 60% were boys. There
were no difference in age or sex-distribution between QFT
consistent positives, QFT reverters and QFT negative controls.
Among the study subjects 46 out of 52 were BCG vaccinated (1
QFT consistent positive with missing data) whereas 36/52 had a
scar present. Comparing QFT consistent positives with reverters,
significantly fewer were vaccinated (16/20 versus 21/21,
p = 0.048), whereas there was no difference in the presence of a
BCG scar.
Ethics Statement
The study was approved by the institutional review board at St.
John’s Medical College, Bangalore, India, an independent
contracted ethics review committee of the Aeras Global TB
Vaccine Foundation, and the Ministry of Health Screening
Committee, Government of India (No. 5/8/9/52/2006-ECD-I
dt. 10.11.2006).
PBMC sample processing
PBMCs were isolated from 16 ml peripheral blood collected on
2 Cell Preparation Tubes per subject, according to the manufac-
turer’s instructions (BD Biosciences). Isolated cells were resus-
pended in FBS (80%) with DMSO (20%) (Sigma) (volume of
diluent equal to the volume of the cell suspension) and
immediately frozen at 280uC for 12 hours, transferred to 2
152uC for typically a week, then transported to the Biorepository
liquid N2 freezers at St. John’s Research Institute. Selected
samples were then shipped in liquid N2 (MVE Vapor Shipper) to
Oslo University Hospital. PBMC were thawed by drop-wise
resuspension in preheated RPMI 1640 (BioWittakre) with 10%
FBS (Sigma) and 1% L-glutamine (Lonza, BioWhittaker) and left
over-night. Cell counts and viability were assessed on Tryphan
Blue (Invitrogen) stained cells (Countess, Invitrogen) and in some
samples confirmed by manual counts (Acridine Orange, Sigma).
Only samples with cell viability .70% were used for further
analysis.
In vitro stimulation
PBMCs were assessed for ex vivo responses to peptide pools of
Early Secretory Antigen Target-6 (ESAT-6) (2 mg/mL) and
Purified Protein Derivate (PPD) (10 mg/mL), both provided by
Statens Serum Institute, Copenhagen, Denmark. Staphococcal
Enterotoxin B (SEB; Sigma) and PBS were used for positive and
negative controls, respectively. Approximately 1 million PBMCs in
a total volume of 300 mL were stimulated for 6 hours in 96-well
round bottom plates (Corning Life Sciences) in the presence of
aCD28 (10 mg/mL, clone L293, BD) and aCD49d (10 mg/mL,
clone L25, BD). Samples from the same subject were set up side by
side in the same plate. Brefeldin A (1.0 ml/well) and monensin
(0.7 ml/well) (both from BD) were added to the cell-antigen mix
prior to the 6 h incubation.
Multi-color staining protocol
As CD107a is a degranulation marker, aCD107a-FITC (BD),
was added together with the Golgi inhibitors (BD) prior to
incubation. After stimulation, samples were washed in PBS,
stained with LIVE/DEAD Violet Fixable Dead Cell Stain
(Invitrogen) for 10 min, washed with PBS, and then stained with
aCD3-APC Alexa Fluor 750 (Beckman Coulter), aCD4-PerCP
Cy5.5 (BD), aCD14-PacBlue (BD), CD16-PacBlue (BD), aCD19-
PacBlue (Invitrogen) and aCD45RO-PE Cy5 (BD) for 25 min,
washed twice with FACS buffer (PBS with 2% FBS and 0.01%
sodium azide), fixed and permeabilized for 10 min using Cytofix/
Cytoperm and Perm/Wash Buffer (BD). The cells were then
stained with IFNc-Alexa Fluor 700 (Invitrogen), IL2-APC (BD),
TNFa-PE Cy7 (BD), and perforin-PE (Diaclone) for 30 min and
washed twice with Perm/Wash Buffer. Stained samples were
stored in 1% formaldehyde at 4uC until flowcytometric analysis
Figure 3. The magnitude of cytokine production by single, double and triple-producing MTB-specific CD4+CD45RO+ T cells at
baseline. The magnitude of IFNc, IL2 and TNFa expression measured by mean fluorescence intensity (MFI), by single, double and triple-producing
CD4+CD45RO+ T cell subsets in response to PPD is shown. QFT consistent positives and reverters are indicated by red or blue color, respectively.
Horizontal lines represent median values. Statistical analysis was performed by Mann-Whitney U test.
doi:10.1371/journal.pone.0101224.g003
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(performed within 48 hours). All staining steps and incubations
were performed at room temperature.
Flowcytometric analysis
All samples were run on a BD LSR II flow cytometer (BD
Biosciences), and analyzed using FlowJo Software (version 9.4.1,
Three Star Inc). BD CompBeads were used for compensation. For
each sample, 20 000 events were recorded for quality assessment,
before the storage gate was set to a wide lymphocyte gate based on
forward- and side scatter properties. (Gating strategy is provided as
Figure S1). Samples were excluded from the study if the
lymphocyte gate was poorly defined; if the CD3+CD4+ or
CD3+CD4- cell counts were less than 5000; or if the sample
was lacking a valid positive control (.1% cytokine-producing cells
when stimulated with SEB). When assessing cytokine–positive
cells, the background response to PBS was subtracted. A threshold
for a positive cytokine response was set at a 2-fold increase in cell
count above the background, and samples that did not meet this
requirement were set to zero.
Statistical analysis
The distribution of age, sex and BCG-status between the QFT
categories was assessed by ANOVA and Fisher’s Exact test where
appropriate. For TST, QFT and absolute frequencies of T-cell
subsets (flowcytometric data), non-parametric statistics were
applied as the data were not normally distributed. The TST and
QFT data were assessed by Mann-Whitney U test and Wilcoxon
Signed rank test for unpaired and paired testing, respectively. As
the flowcytometric data on relative frequencies are normalized,
parametric statistics (unpaired T-test with Welch’s correction)
Figure 4. The relationship between the cytokine-producing CD4+CD45RO+ T cells and the QuantiFERON Gold In-Tube (QFT)
response at baseline. The relationship between the absolute frequencies of (A) all IFNc-producing and (B) polyfunctional (IFNc, IL2 and TNFa)
PPD-specific CD4+CD45RO+ T cells and the magnitude of the QFT response are shown. The relationship between the absolute frequencies of
cytokine-producing T-cells in response to SEB is shown for comparison (C and D). Statistical analyses were performed by Spearman’s correlation
coefficient (rho).
doi:10.1371/journal.pone.0101224.g004
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were applied [27]. Correlations were assessed by Spearman’s
Rank Order Correlation. A two-tailed a-level of p,0.05 was
considered significant. Microsoft Office Excel 2003 and GraphPad
Prism version 5 were used for data handling and statistical
analyses.
Results
QuantiFERON-TB Gold In-Tube and Tuberculin Skin Test
responses in QFT consistent positives, reverters and
negative controls
At baseline, the magnitude of QFT and TST responses were
higher in QFT consistent positives compared to QFT reverters
(Figure 1A and 1B) and both were significantly higher than
responses in the QFT consistent negative controls. Among
consistent positives, 19 of 21 had QFT values $0.70 IU/ml, a
suggested upper limit for a ‘‘grey-zone’’ (0.35 to 0.70 IU/mL) in
test interpretation [14], whereas 18 of 21 reverters had either a
baseline value $0.70 IU/ml or a reduction in IFNc-release of $
80% from baseline to the reversion one year later, suggestion true
test reversion [28]. At one year after the first test, the magnitude of
the response in the reverter group was indistinguishable from the
QFT-negatives. More than half of the consistent positives showed
a positive TST at both time points, whereas all reverters had a
TST below the cutoff level of 10 mm at baseline. After one year,
one reverter had a TST $10 mm (Figure 1B).
Characterization of polyfunctional mycobacteria-specific
CD4+ T-cell responses in QFT consistent positives and
reverters
We tested all samples for viability and only samples with a cell
viability of.70% were used for the subsequent analyses. Available
PBMC samples were investigated with regard to cytokine
responses in CD4+ T-cells as well as cytokine responses and
cytotoxic capacity in CD8+ T-cells. As previously reported, the
number of CD8+ T-cells responding to PPD or ESAT-6 were few
[29], and the responses weak [30,31] (not shown). Consistent with
others [32], we also observed few responding cells among
CD45ROlow CD4+ T-cells (not shown), which are mainly naı¨ve
T-cells. In the following we therefore focused on the CD4+
CD45RO+ T-cell subset, which are mainly memory T-cells.
We first asked whether there were qualitative differences in
mycobacteria-specific CD4+CD45RO+ T-cell responses between
QFT consistent positives and reverters at baseline. To assess this
we analyzed the relative frequencies of triple, double and single
cytokine-producing CD4+ T-cells after 6 hours of stimulation with
either PPD or ESAT-6. A high proportion of PPD-reactive CD4+
T-cells were polyfunctional (IFNc+IL2+TNFa+) in both QFT
consistent positives and reverters (median 36% and 59%,
respectively: not significantly different). The proportion of PPD
responsive IFNc+IL2+TNFa+ memory T-cells in both groups had
decreased one year later, most obviously in the reverter group, but
none of these changes were significant. QFT reverters had a
reduced proportion of PPD-reactive IFNc+TNFa+ CD4+ T-cells
compared to the consistent positives at baseline (Figure 2A). One
year later, the proportion of IL2+TNFa+ CD4+ T-cells in QFT
consistent positives fell compared to baseline (reduction in median
from 16% to 0%, p = 0.02). Other subsets did not show any
significant differences between the groups (Figure 2A).
The quantitative differences were more profound. Although (as
noted above) the relative percentages of polyfunctional CD4+ T-
cells were very similar, the magnitude of the response was greater
in the QFT consistent positive group, which at baseline had
significantly higher numbers (absolute frequencies) of PPD-
responsive IFNc+IL2+TNFa+ CD4+ T-cells, IFNc+TNFa+
CD4+ T-cells and IL2+TNFa+ CD4+ T-cells. Although the same
trend of decreasing responses after 1 year was visible in the
quantitative assessment, this was only significant for IFNc+IL2+
TNFa+ CD4+ T-cells from the QFT reverter group (Figure 2B).
With regard to ESAT-6-reactive CD4+ T-cells, we observed
similar trends for relative and absolute frequencies as seen for
PPD, but as some samples did not respond to ESAT-6 and,
consistent with previous studies [29,30,33], the responses were
generally weaker and significance was not obtained for these
changes (data not shown).
Quantitation of IFNc, IL2 and TNFa production on a per
cell basis in PPD-specific CD4+ T-cells
We then asked whether the amount of cytokine produced on a
single cell level was related to polyfunctionality. To assess this we
measured the mean fluorescence intensity (MFI) of IFNc, IL2 and
TNFa by triple, double, and single cytokine-producing CD4+ T-
cells after stimulation with PPD (Figure 3). In most situations,
single-producing T-cells produced significantly less cytokine
compared with subsets producing two or three cytokines
simultaneously. Importantly, with regard to IFNc- production,
polyfunctional CD4+ T-cells produced significantly more IFNc
than all the other cytokine-producing cell subsets (Figure 3).
However, there were no significant differences in MFI between
consistent positives and reverters.
The absolute frequency of PPD-specific IFNc-producing
CD4+ T-cells correlated well with the QuantiFERON-TB
Gold In-Tube response
As the QFT test measures the total amount of secreted IFNc in
response to MTB-specific antigens, we then asked whether the
magnitude of the QFT response correlated with the production of
IFNc at the single cell level, when applying PPD, a less specific
antigen. Should this be the case, the differences in PPD-specific
polyfunctional CD4+ T-cells described between QFT consistent
positives and reverters would very likely be true, despite the limited
sample size and spread in the data for QFT consistent positives
after 1 year. As shown in Figure 4, both the absolute frequency of
all PPD-specific IFNc-producing T-cells as well as the absolute
frequency of polyfunctional T-cells correlated well with the QFT-
response. Notably, these correlations were likely to be underesti-
mated as serial dilutions for QFT responses .10 IU/mL were not
performed. In comparison, no correlation could be found for SEB
stimulated cells and the QFT response (Figure 4C–D). This
indicates: Firstly, that the polyfunctional T-cell responses to PPD
measured here, reflects specific anti-MTB immune reactivity.
Secondly, that the absolute frequency of PPD-specific polyfunc-
tional CD4+ T-cells are likely to vary in concordance with the
QFT response, hereby supporting a decline in conjunction with
QFT reversion.
Discussion
To our knowledge, this is the first prospective study designed to
assess the dynamics of mycobacteria-specific T-cell responses at
the single cell level in QFT consistent positives compared to QFT
reverters. Our results showed that the proportion (relative
frequency) of PPD-specific polyfunctional (IFNc+IL2+TNF+)
CD4+ T-cells was high in both groups. Except for a small
difference in the proportion of IFNc+TNFa+ CD4+ T-cells (QFT
consistent positives.reverters), we found no differences in the
relative frequency of cytokine-producing CD4+ T-cells at baseline
Frequencies of Polyfunctional T-Cells Correlate with IGRA-Responses
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between the groups. With regard to absolute frequencies, QFT
reverters displayed lower numbers of polyfunctional (IFNc+IL2+
TNF+) and double-producing (IFNc+TNFa+ and IL2+TNFa+)
CD4 T-cells. One year later the PPD-specific T-cell responses
remained unchanged in QFT consistent positives, whereas QFT
reverters had reduced absolute frequencies of polyfunctional T-
cells which were not different from QFT negative controls.
It has been suggested that polyfunctional CD4+ T-cells are
important mediators of protective immunity in MTB infected
subjects. Moreover, QFT reversion has been suggested as a good
prognostic marker with regard to risk of TB progression in LTBI
subjects[14–18]. We therefore hypothesized that the quality and/
or the magnitude of mycobacteria-specific polyfunctional T-cells
were higher in QFT positive subjects who later became QFT
negative compared to consistent positives. We found that both
QFT consistent positives and reverters had high relative frequen-
cies of polyfunctional CD4+ T-cells, but observed no difference
between the groups at any time point. Importantly, the
distribution of the PPD-specific cytokine-producing T-cells in
both QFT consistent positive and reverters reported here is
comparable with findings in the LTBI group reported by Harari
et al., and very different from TB patients in the same study [26].
However, our findings do not support the hypothesis that
increased relative frequencies of polyfunctional mycobacteria-
specific T-cells is associated with the reduced risk of TB
progression seen in QFT reverters [14–18].
To our knowledge, no prospective studies on LTBI adults have
evaluated the protective effect/prognostic value of polyfunctional
mycobacteria-specific T-cells, but results from cross-sectional
studies comparing LTBI subjects with TB patients are used as
arguments for or against a protective effect of polyfunctional
CD4+ T-cells in TB progression [22,30–32,34]. The only
prospective study in humans so far published was performed on
BCG vaccinated infants and concluded that the absolute
frequencies of mycobacteria-specific polyfunctional CD4+,
CD8+ and cd+ T-cells did not correlate with TB protection
[35]. Interestingly, in a mouse model of vaccine-induced
immunity, the absolute frequencies of polyfunctional lung-resident
mycobacteria-specific CD8+ and CD4+ T-cells correlated with
protection whereas high levels in the spleen did not [24],
indicating that tissue-specific distribution might be important.
We found that QFT reverters had lower absolute frequencies of
PPD-specific polyfunctional CD4+ T-cells in peripheral blood at
baseline compared to consistent positives. Furthermore, the
frequencies of the polyfunctional T-cells in reverters were further
reduced after one year (and became not significantly different from
QFT negative controls). As opposed to the continued presence of
mycobacteria-specific polyfunctional CD4+ T-cells in QFT
consistent positives, our findings in the reverter group likely
reflects a transient immune response after MTB exposure.
We also found that PPD-stimulated CD4+ T-cells expressing
more than one cytokine produced more cytokine on a per cell basis
than single-positive cells. This is in keeping with the concept that
polyfunctional T-cells have a stronger protective effect in MTB-
infection [22]. Therefore, it might be surprising that few studies
support the concept that high proportions and/or high absolute
frequencies of these cells in peripheral blood in latency are
correlates of protection from TB progression. This may be because
the presence and localization of polyfunctional T-cells at infection
seem crucial as high numbers in the lung shortly after infection are
protective [2,24,36,37] by their capacity to restrict bacterial
replication and thus promote clearance or successful containment
[38–40]. In this regard, one might argue, that in case of re-
infection, QFT consistent positives are more likely than reverters
to have adequate numbers of circulating memory T-cells capable
of rapid elimination/containment of new MTB bacilli. On the
other hand, mouse models suggest that repeated mycobacterial
exposure (BCG-vaccination) in already MTB infected mice
increased the lung damage independent of the expression of IFNc
in the lesion[41–43].
The QFT assay measures the total production of IFNc in
response to three MTB-specific antigens and does not differentiate
between different types of cytokine-producing T-cells. As we
report good correlation between the magnitude of the QFT
response and the absolute frequencies of PPD-specific polyfunc-
tional CD4+ T-cells, the rather simple QFT assay, seems, in fact, a
good surrogate marker for the numbers of mycobacteria-specific
(probably MTB-specific) polyfunctional T-cells in peripheral blood
of LTBI individuals. This finding questions the rationale for
performing elaborate flow cytometry assays on peripheral blood
samples in the search for ‘‘protective biomarkers’’. The finding
that QFT levels correlated well with the total number of PPD-
specific IFNc-producing T-cells further strengthens the validity of
our results, and suggests little interference by BCG-vaccination
and NTM-exposure. Notably, BCG-vaccination at birth has little
influence on the TST response [4].
Conclusions
Our findings show that mycobacteria-specific polyfunctional
(IFNc+IL2+TNF+) CD4+ memory T-cells are the most frequent
cytokine-producing cells in LTBI individuals and that these cells
are very efficient cytokine-producers compared to single-cytokine
producing T-cells. Contrary to our starting hypothesis, our data do
not support that the relative or absolute frequencies of PPD-
specific polyfunctional CD4+ T-cells in peripheral blood can
explain the reduced risk of TB progression observed in QFT
reverters. Contrary, absolute frequencies of these cells correlated
with the QFT-response, suggesting that this readout reflects the
antigen load, similar to that shown for IGRA-responses in non-
human primates [44]. Our data also supports earlier speculations
on the requirement for persistent or recurrent MTB exposure to
maintain specific IFNc-responses [15,16,18,45]. The mechanisms
behind QFT reversion requires further exploration. Notably, we
cannot draw firm conclusions on the risk of TB progression in
QFT consistent positives. Both QFT consistent positives and
reverters were infected at least one year before the end time point
of this study, but progression to TB at a later time point cannot be
excluded. The TB Trials Study group has prospectively collected
longitudinal PBMC samples from the 6644 subjects enrolled in the
ACS, amongst whom some progressed to TB during the 2-year
surveillance. Work on this analysis is ongoing and hopefully, these
samples will allow us to identify biomarkers to predict TB
progression in LTBI subjects.
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